1Brück, W (2005) Clinical implications of neuropathological findings in multiple sclerosis. J Neurol 252, III/10–III/14.
2Harbige, LS & Sharief, MK (2007) Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. Br J Nutr 98, Suppl. 1, S46–S53.
3Stinissen, P, Raus, J & Zhang, J (1997) Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol 17, 33–75.
4Brown, KA (2001) Factors modifying the migration of lymphocytes across the blood–brain barrier. Int Immunopharmacol 1, 2043–2062.
5Hunter, SF & Hafler, DA (2000) Ubiquitous pathogens. Links between infection and autoimmunity in MS? Neurology 55, 164–165.
6Adams, CWM (1977) Pathology of multiple sclerosis: progression of the lesion. Br Med Bull 33, 15–20.
7Caret, RL, Denniston, KJ & Topping, JJ (1997) . In Principles and Applications of Inorganic, Organic and Biological Chemistry, 2nd ed., pp. 379–407 [Wheatley, CH, editor]. Boston: McGraw-Hill.
8Manzoli, FA, Stefoni, S, Manzoli-Guidotti, L, et al. (1970) The fatty acids of myelin phospholipids. FEBS Lett 10, 317–320.
9Barenholz, Y & Cevc, G (2000) . In Physical Chemistry of Biological Surfaces, pp. 171–241 [Baszkin, A and Norde, W, editors]. New York: Marcel Dekker.
10Koay, ESC & Walmsley, N (1999) . In A Primer of Chemical Pathology, pp. 191–211. Singapore: World Scientific.
11Williams, EE (1998) Membrane lipids: What membrane physical properties are conserved during physiochemically-induced membrane restructuring? Am Zool 38, 280–290.
12Harlos, K & Aibl, H (1981) Hexagonal phases in phospholipids with saturated chains: phosphatidylethanolamines and phosphatidic acids. Biochemistry 20, 2888–2892.
13Calder, PC (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 77, 327–335.
14Khanapure, SP, Garvey, DS, Janero, DR, et al. (2007) Eicosanoids in inflammation: biosynthesis, pharmacology and therapeutic frontiers. Curr Top Med Chem 7, 311–340.
15Tsang, WM, Belin, J, Monro, JA, et al. (1976) Relationship between plasma and lymphocyte linoleate in multiple sclerosis. J Neurol Neurosurg Psychiatry 39, 767–771.
16Cheravil, GD (1984) Sialic acid and fatty acid concentrations in lymphocytes, red blood cells and plasma from patients with multiple sclerosis. J Neurol Sci 63, 1–10.
17Fisher, M, Johnson, MH, Natale, AM, et al. (1987) Linoleic acid levels in leucocytes, platelets, and serum of multiple sclerosis patients. Acta Neurol Scand 76, 241–245.
18Kurtzke, JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452.
19Giovannoni, G, Miller, DH, Losseff, NA, et al. (2001) Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol 248, 487–495.
20Sellner, J, Greeve, I & Mattle, HP (2008) Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Mult Scler 14, 981–984.
21Naing, L, Winn, T & Rusli, BN (2006) Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci 1, 9–14.
22Folch, J, Lees, M & Sloane Stanley, GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497–509.
23Van Jaarsveld, PJ, Smuts, CM, Tichelaar, HY, et al. (2000) Effect of palm oil on plasma lipoprotein concentrations and plasma low-density lipoprotein composition in non-human primates. Int J Food Sci Nutr 51, S21–S30.
24Gilfillan, AM, Chu, AJ, Smart, DA, et al. (1983) Single plate separation of lung phospholipids including desaturated phosphatidylcholine. J Lipid Res 24, 1651–1656.
25Bagga, D, Wang, L, Farias-Eisner, R, et al. (2003) Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 100, 1751–1756.
26Simopoulos, AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21, 495–505.
27De Pablo, MA & De Cienfuegos, GA (2000) Modulatory effects of dietary lipids on immune system functions. Immunol Cell Biol 78, 31–39.
28Horrobin, DF (1999) . In Phospholipid Spectrum Disorder in Psychiatry, pp. 3–16 [Peet, M, Glen, I and Horrobin, DF, editors]. Carnforth, UK: Marius Press.
29Rappaport, RS & Dodge, GR (1981) Prostaglandin E inhibits the production of human IL-2. J Exp Med 155, 943–948.
30Yoneyama, S, Miura, K, Sasaki, S, et al. (2007) Dietary intake of fatty acids and serum C-reactive protein in Japanese. J Epidemiol 17, 86–92.
31Petersson, H, Basu, S, Cederholm, T, et al. (2007) Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br J Nutr 99, 1186–1189.
32Clarke, R, Shipley, M, Armitage, J, et al. (2008) Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. Br J Nutr .
33Petersson, H, Lind, L, Hulthe, J, et al. (2008) Relationship between serum fatty acid composition and multiple markers of inflammation and endothelial function in an elderly population. Atherosclerosis 203, 298–303.
34Giovannoni, G, Thorpe, JW, Kidd, D, et al. (1996) Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 60, 20–26.
35Zamaria, N (2004) Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev 44, 273–282.
36Horrobin, DF & Manku, MS (1990) . In Omega-6 Essential Fatty Acids. Pathophysiology and Roles in Clinical Medicine, pp. 21–49 [Horrobin, DF, editor]. New York: Liss Inc.
37Sprecher, H (1982) Biochemistry of essential fatty acids. Prog Lipid Res 20, 13–22.